| Identification | Back Directory | [Name]
4-Thiazolecarboxylic acid, 2-[[4-(aminosulfonyl)benzoyl]amino]-, cyclopropylmethyl ester | [CAS]
2480284-01-1 | [Synonyms]
hCAI/II-IN-4
4-Thiazolecarboxylic acid, 2-[[4-(aminosulfonyl)benzoyl]amino]-, cyclopropylmethyl ester | [Molecular Formula]
C15H15N3O5S2 | [MOL File]
2480284-01-1.mol | [Molecular Weight]
381.43 |
| Hazard Information | Back Directory | [Uses]
hCAI/II-IN-4 (compound 6d) is a potent dual hCA I/II inhibitor with Ki values of 16.95, 15.22 and 27.04 nM for hCA I, hCA II and hCA Ⅸ, respectively. hCAI/II-IN-4 has anti-hypoxia activities and low toxicity. hCAI/II-IN-4 can be used for acute mountain sickness (AMS) research[1]. | [in vivo]
hCAI/II-IN-4 (compound 6d) (400-2000 mg/kg; p.o.; Male BLAB/c mice of hypoxia) has no apparent toxic effect in vivo[1]. | Animal Model: | Male BLAB/c mice of hypoxia[1] | | Dosage: | 400, 500 and 2000 mg/kg | | Administration: | Oral administration | | Result: | Prolonged the survival time of mice by 29.3% compared with that of the blank control group. |
| [References]
[1] Yang C, et al. N-Quinary heterocycle-4-sulphamoylbenzamides exert anti-hypoxic effects as dual inhibitors of carbonic anhydrases I/II. Bioorg Chem. 2020 Jul;100:103931. DOI:10.1016/j.bioorg.2020.103931 |
|
|